Antibodies to NGAL for Detection of Cancer and Kidney Damage
Inventors: Michael Gould, Jill Haag
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in unique antibodies to neutrophil gelatinase-associated lipocalin (NGAL).
Neutrophil gelatinase-associated lipocalin (NGAL) is a recently discovered cytokine. Because many types of cells produce NGAL in response to injury, it provides a biomarker for several chronic conditions. NGAL can be used in a diagnostic assay to detect certain types of cancer cells. It serves as a strong indicator of kidney damage, and may be useful to monitor other chronic conditions as well.
UW-Madison researchers have developed purified antibodies to NGAL. These unique antibodies can be used in immunoassays for the diagnosis and prognosis of some types of cancer, renal failure and other diseases.
- Immunoassays for cancer, kidney damage and other chronic conditions
- Provides unique antibodies against NGAL
For More Information About the Inventors
- Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., and Gould M.N. 1998. Heterogeneous Expression of the Lipocalin N-gal in Primary Breast Cancers. Int. J. Cancer 79, 565-572.